Cargando…

A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe

BACKGROUND: Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days. A study was undertaken in Europe to confirm lotilaner’s safety and anti-ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavalleri, Daniela, Murphy, Martin, Seewald, Wolfgang, Drake, Jason, Nanchen, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664821/
https://www.ncbi.nlm.nih.gov/pubmed/29089058
http://dx.doi.org/10.1186/s13071-017-2478-9
_version_ 1783275068490514432
author Cavalleri, Daniela
Murphy, Martin
Seewald, Wolfgang
Drake, Jason
Nanchen, Steve
author_facet Cavalleri, Daniela
Murphy, Martin
Seewald, Wolfgang
Drake, Jason
Nanchen, Steve
author_sort Cavalleri, Daniela
collection PubMed
description BACKGROUND: Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days. A study was undertaken in Europe to confirm lotilaner’s safety and anti-tick efficacy in client-owned dogs. METHODS: In this assessor-blinded study, dogs were enrolled at 19 clinics in Germany, Hungary and Portugal. Qualifying households with no more than three dogs were randomized in an approximate 2:1 ratio to a lotilaner or fipronil/(S)-methoprene (FSM) (Frontline® Combo Spot-on, Merial) treatment group. One household dog with at least three live attached ticks was the primary dog. Treatments were dispensed Days 0, 28 (± 2) and 56 (± 2) for owner administration to all household dogs. Tick counts were performed on primary dogs Days 7 (± 1), and ±2 days on Days 14, 21, 28, 42, 56, 70 and 84; supplementary dogs were assessed for safety ± 2 days on Days 28, 56 and 84. Efficacy was assessed by comparing mean Day 0 live attached tick counts with subsequent counts. RESULTS: The most frequently retrieved ticks were Ixodes ricinus, Dermacentor reticulatus and Rhipicephalus sanguineus (sensu lato), with Ixodes hexagonus also present. In the lotilaner group (n = 127) geometric mean tick count reductions were at least 98% from the first post-treatment visit (Day 7) through Day 56, when efficacy was 100%. For FSM (n = 68), efficacy remained at least 96% through Day 84, but at no point were all dogs free of live attached ticks. Mean counts in lotilaner-treated dogs were significantly lower than FSM-treated dogs on Days 7, 42, 70 and 84 (P < 0.05). Percent efficacy over all post-enrolment visits was 99.3 and 98.3% for lotilaner and FSM groups, respectively (t ((190)) = 2.23, P = 0.0268). Owners successfully administered all treatments, and both products were well-tolerated. CONCLUSION: Under European field conditions, lotilaner flavoured chewable tablets administered monthly, were > 98% effective in eliminating live ticks from the first post-treatment assessment (Day 7) through Day 56 and maintained 100% of dogs tick-free on Days 70 and 84. Lotilaner was safe, providing superior tick control to FSM administered according to the same schedule. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2478-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5664821
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56648212017-11-08 A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe Cavalleri, Daniela Murphy, Martin Seewald, Wolfgang Drake, Jason Nanchen, Steve Parasit Vectors Research BACKGROUND: Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days. A study was undertaken in Europe to confirm lotilaner’s safety and anti-tick efficacy in client-owned dogs. METHODS: In this assessor-blinded study, dogs were enrolled at 19 clinics in Germany, Hungary and Portugal. Qualifying households with no more than three dogs were randomized in an approximate 2:1 ratio to a lotilaner or fipronil/(S)-methoprene (FSM) (Frontline® Combo Spot-on, Merial) treatment group. One household dog with at least three live attached ticks was the primary dog. Treatments were dispensed Days 0, 28 (± 2) and 56 (± 2) for owner administration to all household dogs. Tick counts were performed on primary dogs Days 7 (± 1), and ±2 days on Days 14, 21, 28, 42, 56, 70 and 84; supplementary dogs were assessed for safety ± 2 days on Days 28, 56 and 84. Efficacy was assessed by comparing mean Day 0 live attached tick counts with subsequent counts. RESULTS: The most frequently retrieved ticks were Ixodes ricinus, Dermacentor reticulatus and Rhipicephalus sanguineus (sensu lato), with Ixodes hexagonus also present. In the lotilaner group (n = 127) geometric mean tick count reductions were at least 98% from the first post-treatment visit (Day 7) through Day 56, when efficacy was 100%. For FSM (n = 68), efficacy remained at least 96% through Day 84, but at no point were all dogs free of live attached ticks. Mean counts in lotilaner-treated dogs were significantly lower than FSM-treated dogs on Days 7, 42, 70 and 84 (P < 0.05). Percent efficacy over all post-enrolment visits was 99.3 and 98.3% for lotilaner and FSM groups, respectively (t ((190)) = 2.23, P = 0.0268). Owners successfully administered all treatments, and both products were well-tolerated. CONCLUSION: Under European field conditions, lotilaner flavoured chewable tablets administered monthly, were > 98% effective in eliminating live ticks from the first post-treatment assessment (Day 7) through Day 56 and maintained 100% of dogs tick-free on Days 70 and 84. Lotilaner was safe, providing superior tick control to FSM administered according to the same schedule. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2478-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-01 /pmc/articles/PMC5664821/ /pubmed/29089058 http://dx.doi.org/10.1186/s13071-017-2478-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cavalleri, Daniela
Murphy, Martin
Seewald, Wolfgang
Drake, Jason
Nanchen, Steve
A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe
title A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe
title_full A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe
title_fullStr A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe
title_full_unstemmed A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe
title_short A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe
title_sort randomized, controlled study to assess the efficacy and safety of lotilaner (credelio™) in controlling ticks in client-owned dogs in europe
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664821/
https://www.ncbi.nlm.nih.gov/pubmed/29089058
http://dx.doi.org/10.1186/s13071-017-2478-9
work_keys_str_mv AT cavalleridaniela arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT murphymartin arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT seewaldwolfgang arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT drakejason arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT nanchensteve arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT cavalleridaniela randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT murphymartin randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT seewaldwolfgang randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT drakejason randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope
AT nanchensteve randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope